Completed Psoriasis trials in South Korea: Trial Insights

Filters: Condition: Psoriasis Status: Completed Country / region: South Korea Clear all

37 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2007	1
2008	2
2009	1
2010	3
2011	1
2012	1
2013	1
2014	4
2016	2
2017	4
2018	6
2019	6
2020	2
2021	1
2022	2

Trials by status
Category	Trials
Completed	37

Top lead sponsors
Category	Trials
AbbVie	6
Boehringer Ingelheim	4
Janssen Research & Development, LLC	4
Pfizer	4
Bristol-Myers Squibb	3
Novartis Pharmaceuticals	3
UCB Biopharma SRL	3
Amgen	2
Eli Lilly and Company	2
Vanda Pharmaceuticals	2

Top conditions
Category	Trials
Psoriasis	37
Arthritis, Psoriatic	9
Arthritis	4
Bronchiolitis Obliterans Syndrome	2
Dermatitis	2
Inflammation	2
Joint Diseases	2
Lymphoma, Follicular	2
Musculoskeletal Diseases	2
Pruritus	2

Trials

Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.

A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study) NCT05758402Not applicableCompletedNovartis PharmaceuticalsStarted 2022
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP NCT05352893Phase 3CompletedVanda PharmaceuticalsStarted 2022
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis NCT04967508Phase 3CompletedSamsung Bioepis Co., Ltd.Started 2021
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis NCT04433442ObservationalCompletedAbbVieStarted 2020
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis NCT04399837Phase 2CompletedBoehringer IngelheimStarted 2020
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea NCT04167462Phase 3CompletedBristol-Myers SquibbStarted 2019
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis NCT04036435Phase 3CompletedBristol-Myers SquibbStarted 2019
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis NCT04015518Phase 2CompletedBoehringer IngelheimStarted 2019
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea NCT03925441ObservationalCompletedAbbVieStarted 2019
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis NCT03782792Phase 2CompletedBoehringer IngelheimStarted 2019
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis NCT03619902Phase 2CompletedVanda PharmaceuticalsStarted 2019
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT03598790Phase 3CompletedUCB Biopharma SRLStarted 2018
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis NCT03624127Phase 3CompletedBristol-Myers SquibbStarted 2018
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) NCT03535194Phase 3CompletedEli Lilly and CompanyStarted 2018
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis NCT03482011Phase 3CompletedEli Lilly and CompanyStarted 2018
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT03410992Phase 3CompletedUCB Biopharma SRLStarted 2018
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT03412747Phase 3CompletedUCB Biopharma SRLStarted 2018
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug NCT03104374Phase 3CompletedAbbVieStarted 2017
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) NCT03104400Phase 3CompletedAbbVieStarted 2017
Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab NCT03099083ObservationalCompletedAbbVieStarted 2017
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) NCT03047395Phase 3CompletedAbbVieStarted 2017
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis NCT02978690Phase 1CompletedBoehringer IngelheimStarted 2016
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age NCT02698475Phase 3CompletedJanssen Research & Development, LLCStarted 2016
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis NCT02207231Phase 3CompletedJanssen Research & Development, LLCStarted 2014
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment NCT02207244Phase 3CompletedJanssen Research & Development, LLCStarted 2014

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory